24/7 Market News Snapshot 11 February, 2025 – IN8bio, Inc. Common Stock (NASDAQ:INAB)

February 11, 2025

DENVER, Colo., 11 February, 2025 (247marketnews.com) – (Nasdaq:INAB) are discussed in this article.
IN8bio, Inc. (Nasdaq:INAB), a clinical-stage biopharmaceutical company specializing in gamma-delta T cell therapies for cancer, has gained significant market attention recently. The stock surged impressively to $0.718, reflecting a remarkable increase of 165.83% from the previous close of $0.270, amid a trading volume of nearly 35 million shares. This bullish trend underscores strong investor interest and positions INAB as a potential growth opportunity in the coming days.

The impressive momentum is bolstered by the company’s announcement of promising clinical results from its ongoing Phase 1 trial of INB-100, an allogeneic gamma-delta T cell therapy for patients with acute myeloid leukemia (AML). Remarkably, 100% of the AML patients treated with INB-100, across both the original and expansion cohorts, remain in complete remission, with a median follow-up of 20.1 months. Several patients have achieved remission durations extending beyond three years, marking a significant advancement in treatment options for this challenging condition.

The promising data reported indicates that the one-year progression-free survival (PFS) and overall survival (OS) rates for treated AML patients stand at an extraordinary 100%. This significantly outperforms historical control groups, where standard treatments typically yield PFS rates around 67.8%. INB-100 has also shown promise among older, high-risk patients, demonstrating a favorable safety profile without reports of cytokine release syndrome or neurotoxicity.

CEO William Ho expressed enthusiasm for INB-100’s potential to redefine treatment standards for AML, reflecting the company’s commitment to delivering transformative therapies. As IN8bio continues its patient enrollment efforts and navigates future regulatory milestones, the market closely watches for continued developments that may enhance the accessibility of this innovative therapy.

Related news for (INAB)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.